The Wall Street Journal: Over-the-counter overdose-reversal drug from nonprofit pharma group wins fast-track U.S. review

Portrait of a afro caucasian couple giving high five isolated over white background

Harm Reduction Therapeutics says it plans to produce 2 million doses of 3-milligram naloxone nasal spray, called Rivive, per year.

You might also like